3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Glioma
8
Glioblastoma
7
Recurrence
3
Osteosarcoma
3
Neuroblastoma
3
Medulloblastoma
3
Ependymoma
3
Central Nervous System Neoplasms
3
Wilms Tumor
2
Sarcoma
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Pheochromocytoma
2
Paraganglioma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Lymphoma, Non-Hodgkin
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Cholangiocarcinoma
2
Brain Neoplasms
2
Xanthogranuloma, Juvenile
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Neuroendocrine Tumors
1
Meningioma
1
Histiocytic Sarcoma
1
Gliosarcoma
1
Familial ependymoma
1
Esthesioneuroblastoma, Olfactory
1
Breast Neoplasms
1
Interventions
Docetaxel
8
Radiotherapy
6
Filgrastim
5
Cisplatin
5
Radiotherapy, Intensity-Modulated
3
Etoposide
3
Erlotinib Hydrochloride
3
Chemotherapy, Adjuvant
3
Cetuximab
3
Capecitabine
3
Bevacizumab
3
sargramostim
2
Peripheral Blood Stem Cell Transplantation
2
Paclitaxel
2
Gemcitabine
2
Cyclophosphamide
2
Carboplatin
2
Acupuncture Therapy
2
vandetanib
1
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
tanespimycin
1
pentetreotide
1
oncogene protein E7, Human papillomavirus type 16
1
olaparib
1
oblimersen
1
lutetium Lu 177 dotatate
1
etoposide phosphate
1
entinostat
1
enasidenib
1
cevimeline
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esthesioneuroblastoma, Olfactory
×
olaparib
×
CNS
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled